口服抗凝药华法林的药物基因组学研究进展  

Progress in the pharmacogenomics of the oral anticoagulant agent warfarin

作　　者：季闽春[1] 沈晓英[1] 徐琳[1] 杨耀芳[1] 

机构地区：[1]复旦大学附属上海市第五人民医院药剂科,上海200240

出　　处：《中国临床药理学杂志》2010年第9期696-700,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：华法林是一个治疗范围窄、剂量个体差异大的口服抗凝药物,决定其维持剂量的有遗传和某些非遗传因素,其中编码代谢酶和维生素K环氧化物降解酶的基因变异是研究最广泛的遗传因素。本文对华法林的药物基因学的部分研究内容进行了综述,以便临床更好开展个体化治疗,减少出血等不良反应。The oral anticoagulant warfarin has a narrow therapeutic range and wide inter- individual dosing requirements, genetic factors together with several non - genetic patient - specific factors are important determi- nants of stable dose requirement for the agent. Genotype for CYP2C9 and vitamin K epoxide reductase complex subunit （ 1 - VKORC1 ） , which en- codes the main functional variants of genes affecting warfarin metabolism and activity, were widely investigated. We reviewed some literatures a- bout pharmacogenomics of warfarin, that may help clinicians to give indi- vidualized therapy on patients, and minimize adverse drug reaction such as bleeding.

关 键 词：华法林 药物基因组学 抗凝 

分 类 号：R973.2[医药卫生—药品] R968[医药卫生—药学]